UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

             CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                       (Date of earliest event reported):

                                  July 22, 2004



                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)





        DELAWARE                          000-29089            06-1562417
------------------------------     -----------------------  -------------------
(State or other jurisdiction of    (Commission file number) (I.R.S. Employer
incorporation of organization)                              Identification No.)





                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)





                                 (212) 994-8200
              (Registrant's telephone number, including area code)








ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.

         (c) Exhibits:

              99.1     Press Release dated July 22, 2004

ITEM 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On July 22, 2004, Antigenics Inc. announced its financial results for the
quarter ended June 30, 2004. The full text of the press release issued in
connection with the announcement is attached as Exhibit 99.1 to this current
report on Form 8-K.

The information in this report on Form 8-K and the Exhibit attached hereto is
being furnished pursuant to Item 12 of Form 8-K, Disclosure of Results of
Operations and Financial Condition. The information shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933
or the Exchange Act, except as expressly set forth by specific reference in such
a filing.












                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          ANTIGENICS INC.

Date: July 22, 2004
                                          By: /s/ Garo H. Armen
                                          -------------------------------------
                                          Garo H. Armen, Ph.D.
                                          Chairman and Chief Executive Officer








                                  EXHIBIT INDEX


The following designated exhibits are filed herewith:

Exhibits:

  99.1   Press Release dated July 22, 2004